Want to see GB:PYC full AI Analyst Report?
PYC Stock Chart & Stats
0.28 p
0.05 p(6.45%)
At close: 4:00 PM EST
0.28 p
0.05 p(6.45%)
Day’s Range― - ―
52-Week Range0.25 p - 0.80 p
Previous CloseN/A
Volume16.21M
Average Volume (3M)2.43M
Market Cap
£2.38M
Enterprise Value1.34M
Total Cash (Recent Filing)£257.00K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding453,208,700
10 Day Avg. Volume1,168,038
30 Day Avg. Volume2,434,740
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.60
Price to Sales (P/S)1.41
P/FCF Ratio-2.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Oncology Modelling ServicesPhysiomics' specialised computational modelling and translational pharmacology focus is a durable competitive advantage in oncology R&D. Deep scientific expertise and platform-driven services create high switching costs, foster repeat client engagements, and support sustained fee-for-service demand from biopharma and academia over months to years.
Strong Recent Revenue ReboundA ~51% revenue rebound in 2025 signals strengthening commercial traction and growing client demand for modelling services. If sustained, higher top-line momentum improves operating leverage potential, broadens reference clients, and provides a clearer runway to scale projects and convert fixed scientific capabilities into steadier contract revenues over the medium term.
Low Leverage Balance SheetZero reported debt and a positive equity base reduce short-term refinancing pressure and interest obligations. This conservatism preserves optionality to fund strategic investments or bridge cash needs via equity if required, giving management flexibility to pursue client wins or product development without near-term debt servicing constraints.
Bears Say
Persistent Cash BurnRecurring negative operating and free cash flow indicates the business is not yet self-funding. Continued cash burn forces reliance on external funding or equity raises, raising dilution risk and constraining the company's ability to invest in scaling capabilities or withstand client payment timing shocks over the coming months without capital actions.
Ongoing Losses And Weak MarginsSustained net losses and negative margins limit retained earnings and reinvestment capacity. Without a clear path to margin improvement, the company may struggle to achieve profitable scalability, increasing the likelihood of further financing needs and reducing resilience to competitive pricing pressure in the services market.
Negative Returns And Dilution RiskA deeply negative ROE reflects value destruction for shareholders and suggests historical investments haven't generated positive returns. Persisting negative returns raise the probability of equity dilution to fund operations, undermining long-term shareholder value and making it harder to attract accretive capital without clear profitability progress.
Physiomics News
PYC FAQ
What was Physiomics PLC’s price range in the past 12 months?
Physiomics PLC lowest share price was 0.25 p and its highest was 0.80 p in the past 12 months.
What is Physiomics PLC’s market cap?
Physiomics PLC’s market cap is £2.38M.
When is Physiomics PLC’s upcoming earnings report date?
Physiomics PLC’s upcoming earnings report date is Sep 24, 2026 which is in 66 days.
How were Physiomics PLC’s earnings last quarter?
Physiomics PLC released its earnings results on Feb 16, 2026. The company reported -0.001 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.001 p.
Is Physiomics PLC overvalued?
According to Wall Street analysts Physiomics PLC’s price is currently Overvalued.
Does Physiomics PLC pay dividends?
Physiomics PLC does not currently pay dividends.
What is Physiomics PLC’s EPS estimate?
Physiomics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Physiomics PLC have?
Physiomics PLC has 453,208,700 shares outstanding.
What happened to Physiomics PLC’s price movement after its last earnings report?
Physiomics PLC reported an EPS of -0.001 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -15.385%.
Which hedge fund is a major shareholder of Physiomics PLC?
Currently, no hedge funds are holding shares in GB:PYC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Physiomics PLC
Founded in 2001 and headquartered in Oxford, UK, Physiomics Plc offers expert consulting services to pharmaceutical enterprises across the United Kingdom, the United States, and the European Union. The company's core specialization lies in outsourced quantitative pharmacology and computational biology. They deliver comprehensive modeling, simulation, and data analysis services primarily focused on oncology research and development, utilizing their proprietary Virtual Tumour predictive software. Additionally, Physiomics is engaged in developing innovative technologies for applications within the field of personalized medicine.